Latest Articles about ENDP

Setback for Endo Health on Opana ER - Analyst Blog

Zacks Equity Research — Tue, 14 May 2013 02:05:22 Z

Endo Health Solutions Inc. ( ENDP ) recently suffered a setback with the US Food and Drug Administration (FDA) turning down its request to prevent the entry of generic versions of the

Earnings Beat at Endo Health, Sales Slip - Analyst Blog

Zacks Equity Research — Thu, 09 May 2013 02:24:39 Z

Endo Health Solutions' ( ENDP ) first quarter 2013 earnings (excluding special items) of $1.09 per share beat the Zacks Consensus Estimate by a penny and increased 25% from the year-ago

Company News for May 8, 2013 - Corporate Summary

Zacks Equity Research — Wed, 08 May 2013 18:26:17 Z

• AECOM Technology Corp (NYSE: ACM ) reported second quarter earnings per share of $0.53, beating the Zacks Consensus Estimate of $0.51 • Endo Health

Back to Neutral on Endo Health - Analyst Blog

Zacks Equity Research — Thu, 07 Mar 2013 00:10:01 Z

We are reverting to a Neutral recommendation on Endo Health Solutions ( ENDP ) from Underperform as we believe that the stock is fairly valued at current levels. Our target price is $32.00.

Actavis Files ANDA for Endo Product - Analyst Blog

Zacks Equity Research — Wed, 06 Mar 2013 02:40:01 Z

Actavis, Inc. ( ACT ) recently announced that it is looking to get its generic version of Endo Health Solutions Inc. 's ( ENDP ) Fortesta (testosterone gel 10mg/0.5g) approved in the

Earnings Beat at Endo Health - Analyst Blog

Zacks Equity Research — Mon, 04 Mar 2013 18:30:01 Z

Endo Health Solutions ' ( ENDP ) fourth-quarter 2012 earnings (excluding special items) of $1.62 per share beat the Zacks Consensus Estimate of $1.56 and increased 15.7% from the year-ago

After-Hours Earnings Report for February 28, 2013 : CRM, GPS, UHS, TEG, NGD, WR, MDVN, ENDP, GXP, MDR, CPNO, SLXP

NASDAQ.com News — Fri, 01 Mar 2013 00:00:05 Z

The following companies are expected to report earnings after hours on 02/28/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Salesforce.com Inc ( CRM ) is

Endo Health draws big call spread

David Russell — Thu, 28 Feb 2013 12:47:14 Z

Endo Health Solutions reports earnings after the bell today, and the bulls are stepping in. optionMONSTER's Heat Seeker monitoring program detected the purchase of about 10,000 April 30 calls

After Hours Most Active for Feb 27, 2013 : F, GRPN, JCI, ABT, ABBV, JCP, GTAT, QQQ, BAC, TLAB, ENDP, ACWI

NASDAQ.com News — Thu, 28 Feb 2013 02:45:04 Z

The NASDAQ 100 After Hours Indicator is down -1.06 to 2,740.2. The total After hours volume is currently 31,871,127 shares traded. The following are the most active stocks for the after

Mid-Day Market Update: Markets Turn Red, Dillard's Tumble On Downbeat Results

Jake L'Ecuyer — Mon, 25 Feb 2013 22:35:39 Z

Midway through trading Monday, the Dow traded down 0.33 percent to 13,954.03 while the NASDAQ fell 0.09 percent to 3,158.89. The S&P also fell, declining 0.33 percent to 1,510.58.

Stock Market News for February 19, 2013 - Market News

Zacks Equity Research — Tue, 19 Feb 2013 19:36:01 Z

Benchmarks finished Friday's trading session slightly higher, following mixed economic numbers and speculation of weak sales from a major retail company. The S&P 500 maintained its

Mid-Afternoon Market Update: RIMM Falls Further, Endo Health Rises on Exploration of a Sale

Jake L'Ecuyer — Thu, 31 Jan 2013 01:22:56 Z

Toward the end of trading Wednesday, the Dow traded down 0.26 percent to 13,918.18 while the NASDAQ was down 0.23 to 3,146.18. The S&P also fell, decreasing 0.28 percent to 1,503.25.

Endo Inks Deal with Indian Company - Analyst Blog

Zacks Equity Research — Wed, 30 Jan 2013 04:45:01 Z

In a bid to establish its presence in the highly sought after Indian market, US based Endo Health Solutions Inc. ( ENDP ) recently inked a deal with GVK Biosciences., Based in India, GVK

Bearish MACD for Endo Health Solutions Inc. - Tale of the Tape

Zacks Equity Research — Tue, 22 Jan 2013 21:01:01 Z

Endo Health Solutions Inc. 's ( ENDP ) MACD indicator has moved into bearish territory with a reading of -0.0773. The Zacks Rank # 5 ("Strong Sell") stock decreased more than

Impax Launches Opana ER Generic - Analyst Blog

Zacks Equity Research — Tue, 08 Jan 2013 00:52:01 Z

Global Pharmaceuticals, the generic division of Impax Laboratories, Inc. ( IPXL ), a specialty pharmaceutical company, recently started shipping its generic version of Endo Health